Objective:The Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study compared the effects of once-monthly paliperidone palmitate with daily oral antipsychotics on treatment failure in adults with schizophrenia.
The intent of this paper is to provide an overview of basic concepts, types, techniques, and experimental studies of the current state-of-the-art Frequency Selective Surfaces (FSSs). FSS is a periodic surface with identical two-dimensional arrays of elements arranged on a dielectric substrate. An incoming plane wave will either be transmitted (passband) or reflected back (stopband), completely or partially, depending on the nature of array element. This occurs when the frequency of electromagnetic (EM) wave matches with the resonant frequency of the FSS elements. Therefore, an FSS is capable of passing or blocking the EM waves of certain range of frequencies in the free space; consequently, identified as spatial filters. Nowadays, FSSs have been studied comprehensively and huge growth is perceived in the field of its designing and implementation for different practical applications at frequency ranges of microwave to optical. In this review article, we illustrate the recent researches on different categories of FSSs based on structure design, array element used, and applications. We also focus on theoretical breakthroughs with fabrication techniques, experimental verifications of design examples as well as prospects and challenges, especially in the microwave regime. We emphasize their significant performance parameters, particularly focusing on how advancement in this field could facilitate innovation in advanced electromagnetics.
Treatment with almotriptan within 1 hour of migraine onset resulted in significantly better clinical outcomes than placebo and tolerability similar to placebo. Acute medications, such as almotriptan, that are both effective and well tolerated may encourage patients to access acute treatment earlier.
Background: Topiramate can improve drinking outcomes via a hypothesized mechanism of facilitating ␥aminobutyric acid function and inhibiting glutaminergic pathways in the corticomesolimbic system. We sought to determine whether topiramate's antidrinking effects are bolstered by improvements in physical and psychosocial well-being.Methods: In a 17-site, 14-week, double-blind, randomized controlled trial, we compared the effects of topiramate (up to 300 mg/d) vs placebo on physical health, obsessional thoughts and compulsions about using alcohol, and psychosocial well-being among 371 alcoholdependent subjects who received weekly adherence enhancement therapy.Results: Topiramate was more efficacious than placebo in reducing body mass index (calculated as weight in kilograms divided by height in meters squared) (mean difference, 1.08; 95% confidence interval [CI], 0.81-1.34; PϽ.001), all liver enzyme levels (PϽ.01 for all comparisons), plasma cholesterol level (mean difference, 13.30 mg/dL; 95% CI, 5.09-21.44 mg/dL; P = .002), and sys-Author Affiliations are listed at the end of this article. Group Information: The members of the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group are listed on page 1198.
Topiramate is generally safe and reasonably well tolerated for the prevention of migraine in adults. The most common topiramate-associated AEs were mild or moderate in severity and occurred more frequently during titration to target doses.
Prior to treatment, the presence of migraine-associated characteristics including aura, allodynia-associated symptoms, photophobia, phonophobia, and nausea were similar for both MRM and nonMRM attacks. The pretreatment levels of pain intensity and functional disability were likewise similar across the migraine subtypes. Almotriptan was equally effective in the treatment of both MRM and nonMRM attacks and was associated with an adverse event profile that was similar to placebo treatment.
Compared with placebo-treated patients, topiramate 100 mg/day appears to contribute to reductions in migraine-related limitations on daily activities and emotional distress beginning as early as week 4 and continuing up to week 16 after treatment. Physician's Global Impression of Change results are very similar with Subject's Global Impression of Change, indicating concordance between the physician's and the subject's assessment of improvement.
Abstract-A novel design of planar dual and triple narrow-band bandstop filter is presented by adopting the proposed meandered slot defected microstrip structure (MS-DMS) and the simplified spiral microstrip resonator (SSMR). Through this design, the stopbands of the dual-and triple-band bandstop filters can be individually controlled and the improved spurious responses are achieved. First, the fundamental and the first spurious resonances of the MS-DMS and SSMR are analyzed to provide the design rules. Then, by utilizing the prominent stopband of the MS-DMS and the stopband produced by the SSMR coupled to main microstrip line, a dual narrowband bandstop filter is constructed before its design procedure is outlined. Based on above investigations, a triple narrow-band bandstop filter is implemented by inserting extra SSMRs to another side of the main microstrip line of the dual-band filter to generate a new stopband. To verify the aforementioned design concepts, a dual and triple narrow-band bandstop filter are designed, simulated and tested. Both the simulation and measurement indicate that the fabricated filters exhibit good stopband/passband performance and improved first spurious resonance. Moreover, these filters are simple to design and quite compatible with planar fabrication technique, making them very attractive for practical applications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.